Somahlution is a privately-held global biotechnology company headquartered in Jupiter, Florida that develops and markets innovative products that address critical unmet medical needs, using breakthrough technologies to advance human health. Somahlution’s portfolio of products are designed to reduce the disease burden of Ischemia Reperfusion Injury (IRI) and address unmet needs for tissue grafting, organ transplant and other surgical indications. The products are based on a proprietary and innovative platform technology called GALA that is licensed from The U.S. Department of Veterans Affairs.
Using the GALA platform technology, the Company has developed a portfolio of products including a first-in-class product, DuraGraft®. DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure. DuraGraft enhances CABG outcomes by significantly reducing major cardiac events such as repeat revascularization, myocardial infarction and MACE.
DuraGraft was launched in Europe and other global markets in 2015 for CABG and Peripheral Bypass Indications and is expected to launch for use in CABG surgery in the United States in 2017.
The following attributes have forged Somahlution’s path to success: